000 01724pab a2200241 454500
008 150901b2005 xxu||||| |||| 00| 0 eng d
040 _aTata Memorial Hospital
041 _aEnglish
082 _a
_b
100 _aDobrowsky W
245 _aAk-2123 (Sanazol) as a radiation sensitizer in the treatment of stage iii cancer cervix: Initial results of an IAEA multicentre randomized trial.
260 _c2005
300 _a75-78
490 _a
_vVol 1 Issues 2
520 _aPURPOSE : AK-2123, a nitrotriazole hypoxic cell sensitizer has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage IIIA and IIIB. MATERIALS AND METHODS : A total of 333 patients were randomised between May1995 and December1998. Patients were randomised to either standard radical treatment (radiation therapy alone, RT) or standard radical radiotherapy and additional administration of AK-2123 (RT+AK-2123). The total dose of 45-50.8 Gy was delivered in 20 to 28 fractions over 4 to 5 1/2 weeks. The dose to the central disease was escalated to a radiobiologically equivalent dose of 70 Gy by external beam or brachytherapy, in accordance with each centres individual practice. In the study arm, patients received 0.6 g/sqm AK-2123 by intravenous administra
650 _aRCT, cervix cancer, India,,
650 _a
700 _aJayatilake, R S
700 _aHuigol, N G
700 _a
773 _078381
_aJournal of Cancer Research and Therapeutics
906 _aApr-Jun
999 _c25719
_d25719